Compare Standard Lithium Ltd (SLI) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Standard Lithium Ltd vs BIO-TECHNE Corp — how do they compare? Standard Lithium Ltd trades at $2.27 (market cap $523.89M), while BIO-TECHNE Corp trades at $71.63 (market cap $11.16B). The key difference: BIO-TECHNE Corp is far larger — about 21.3× Standard Lithium Ltd's market cap, and BIO-TECHNE Corp pays a 0.45% dividend while Standard Lithium Ltd pays none. Which is the better fit depends on your goals.
| SLI | TECH | |
|---|---|---|
Market Cap | $523.89M | $11.16B |
Sector | Basic Materials | Health |
52-Week High | $5.65 | $72.12 |
52-Week Low | $2.15 | $43.31 |
Enterprise Value | $383.09M | $11.24B |
Dividend Yield | — | 0.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Standard Lithium (SLI) trades at $2.15, down 4.87% today, reflecting bearish technical signals and negative profitability metrics. The company reported a net loss of $48.40 million for 2025, though it secured a $225 million DOE grant and key construction contracts for its Arkansas lithium project. Analyst consensus remains unanimously bullish with three buy ratings, citing progress toward a final investment decision in 2026.
The investment case hinges on successful project execution, with upside potential from lithium demand and federal funding, but risks include sustained cash burn and delays. The stock's current valuation at 1.52 times book value may attract value investors, yet profitability challenges and bearish technical trends warrant caution amid high operational expenditures.
Bio-Techne (TECH) trades at $71.64, down 0.67% today, near its 52-week high following Merck KGaA's $73 per share acquisition offer. The stock shows bullish technical signals with strong moving averages, though RSI indicates overbought conditions. Recent earnings have been mixed, with Q4 2025 beating expectations but Q1 2026 missing. The company maintains solid gross margins of 64.96% but faces declining net income margins, down to 6.01% in 2025 from 25.09% in 2023.
The outlook is heavily influenced by the pending acquisition, offering a clear exit near current levels. Risks include shareholder litigation over deal fairness and fundamental profitability pressures. With a high P/E of 103.03, the stock's upside appears capped without the deal, while the $73 bid provides a near-term floor. Investors should weigh acquisition completion probability against operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Standard Lithium Ltd
Standard Lithium Ltd. is a company focused on the development of lithium projects in North America, with a primary focus on extracting lithium from brine resources. Their flagship projects aim to utilize proprietary, advanced direct lithium extraction (DLE) technologies to produce high-purity lithium compounds in an environmentally responsible manner. The company seeks to become a key domestic supplier to the growing electric vehicle and battery storage markets.
Read more on SLI →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
